The Netherlands-based ProQR Therapeutics has concluded dosing patients in a Phase Ib clinical trial of QR-010 for the treatment of patients with cystic fibrosis.

QR-010 is a RNA-based oligonucleotide being developed to target mRNA in patients having the F508del mutation, which is a deletion of three coding base pairs in the CFTR gene.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Designed for self-administration through a handheld aerosol delivery device called eFlow Nebuliser, QR-010 is intended to bind to the defective CFTR mRNA for restoring CFTR function.

The randomised, double-blind, placebo-controlled Phase Ib trial evaluated the safety, tolerability and pharmacokinetics of 6.25mg, 12.5mg, 25mg and 50mg dose levels of QR-010 in solution per dose given through inhalation.

Conducted at 26 centres in Europe and North America, the trial included adults with mild disease and a baseline predicted FEV1 value of greater than 70%.

"QR-010 has the potential to be an innovative RNA therapy for patients with CF due to the F508del mutation."

ProQR Therapeutics chief medical officer Noreen Henig said: “QR-010 has the potential to be an innovative RNA therapy for patients with CF due to the F508del mutation. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Completion of the Phase Ib study is an important step in development, and builds upon the pre-clinical data and positive PQ-010-002 study where QR-010 demonstrated a direct effect on restoring CFTR function.”

The 28-day trial included a total of 64 patients in eight cohorts, one to four of which were given a single dose of QR-010, while five to eight were administered with 12 doses.

Exploratory efficacy endpoints such as sweat chloride, weight gain and change in FEV1 are currently being evaluated, with plans to report the trial’s top-line results in the last week of next month.